Bosentan is the active ingredient in the medication.It is available in various formulations, including tablets and oral suspension.
Treatment of pulmonary arterial hypertension (PAH) in adults.
Treatment of PAH in children aged 1 year or older.
Treatment of sclerodermarelated digital ulcers in adults.
Lupibose 125mg Tab (Bosentan) is an endothelin receptor antagonist. It works by blocking the action of endothelin, a powerful vasoconstrictor, which helps to relax and widen blood vessels, improving blood flow and reducing pressure in the lungs.
Store Bosentan tablets at room temperature, away from moisture and heat. Keep them in their original container and keep them out of the reach of children and pets.
The dosage of Bosentan will vary depending on your individual needs and the condition being treated.
It is usually taken twice daily with or without food.
Your doctor will provide specific instructions on how to take Bosentan.
Headache
Flulike symptoms
Fatigue
Diarrhea
Nausea
Abdominal pain
Liver function abnormalities
Increased risk of anemia
Fluid retention
Low blood pressure
Heart rhythm problems
Skin rash
Alcohol may increase the risk of side effects. Consult your doctor before consuming alcohol while taking Bosentan.
Bosentan may cause dizziness or drowsiness. Avoid driving or operating machinery until you know how it affects you.
Bosentan is known to be harmful to a developing fetus. It is contraindicated in pregnancy. It is also unknown if Bosentan passes into breast milk. Discuss with your doctor about the risks and benefits before taking Bosentan if you are pregnant or breastfeeding.
The safety and efficacy of Bosentan in children under 1 year old have not been established.
Bosentan may affect kidney function. Your doctor will monitor your kidney function during treatment.
Bosentan may cause liver damage. Your doctor will monitor your liver function during treatment.
The official prescribing information for Bosentan.
The website of the Food and Drug Administration (FDA).
The website of the European Medicines Agency (EMA).
